Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study

Background Patients with severe haemophilia have impaired haemostatic response, delayed clot formation and fibrin clots that are vulnerable to fibrinolysis. Emicizumab is a bispecific antibody that mimics activity of activated factor VIII (FVIII) and increases haemostatic capacity to the level of mo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haemophilia : the official journal of the World Federation of Hemophilia 2021-11, Vol.27 (6), p.1002-1006
Hauptverfasser:	Janbain, Maissa, Enjolras, Nathalie, Bolbos, Radu, Brevet, Marie, Bordet, Jean‐Claude, Dargaud, Yesim
Format:	Artikel
Sprache:	eng
Schlagworte:	Amputation Antifibrinolytic agents Bispecific antibodies Bleeding Coagulation factors Disease prevention emicizumab Fibrin Fibrinolysis haemophilia A Hematology Hemophilia Injection joint bleed Knee Life Sciences & Biomedicine Magnetic resonance imaging Patients Prophylaxis Rodents Scanning electron microscopy Science & Technology Thrombin tranexamic acid Trauma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!